Tetrabenazine Tablets Application Scope

Tetrabenazine Tablets are primarily indicated for the treatment of hyperkinetic movement disorders, particularly in conditions such as Huntington’s disease, where patients experience uncontrollable movements known as chorea. Tetrabenazine works by reducing the levels of dopamine in the brain, which helps to control these abnormal movements. It is also used in the treatment of other conditions associated with tics and Tourette syndrome, as well as certain drug-induced movement disorders.

Tetrabenazine Tablets Characteristics

Ingredients: Each tablet contains tetrabenazine as the active ingredient.
Properties: Tetrabenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor that depletes monoamines such as dopamine, serotonin, norepinephrine, and histamine from nerve terminals, leading to a reduction in hyperkinetic movements.
Specifications: Available in tablet form with varying strengths, commonly 12.5 mg and 25 mg.

Packaging Specification:

Packaging: Supplied in bottles containing 112 tablets.
Storage: Store at controlled room temperature, 20°C to 25°C (68°F to 77°F).
Shelf Life: Refer to the expiration date on the packaging.
Approval Number: Refer to the regulatory approval number on the packaging.
Manufacturer: Refer to the manufacturer’s information on the packaging.

Guidelines For The Use Of Tetrabenazine Tablets

Dosage and Administration: The initial recommended dose is 12.5 mg once daily, which may be increased gradually by 12.5 mg increments each week to determine the optimal dose. The maximum recommended daily dose is 100 mg, with individual doses not exceeding 25 mg. Doses above 50 mg per day should be administered in three divided doses.
Adverse Reactions: Common adverse reactions include sedation, somnolence, fatigue, insomnia, depression, suicidal thoughts, akathisia, anxiety, and nausea.

Medication Limitations

Contraindications: Contraindicated in patients who are actively suicidal, have untreated or inadequately treated depression, or have hepatic impairment. Also contraindicated in patients taking monoamine oxidase inhibitors (MAOIs) or reserpine.
Precautions: Monitor for emergence or worsening of depression, suicidality, or unusual changes in behavior. Use caution when treating patients with a history of depression or prior suicide attempts or ideation.

Tetrabenazine Tablets Interactions

Interactions: Concomitant use with strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) may increase the exposure to tetrabenazine and its metabolites, necessitating dose adjustments. Avoid use with MAOIs.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from HongKong DengYue Medicine. It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.